GE Healthcare Acquires PAA Laboratories GmbH

GE Healthcare Acquires PAA Laboratories GmbHGE Healthcare Acquires PAA Laboratories GmbH in a bid to reinforce and strengthen biopharmaceutical manufacture segment of the company.

The company announced today that they have entered a definitive agreement to acquire PAA Laboratories for an undisclosed amount.

“The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally,” said Kieran Murphy, President and CEO of GE Healthcare Life Sciences. “GE Healthcare Life Sciences is well known for its expertise in the “downstream” processes of biopharmaceutical manufacturing. Adding “upstream” capabilities will enable us to provide an end-to-end, fully integrated service to our customers. We believe that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product and reduce time to market.”

GE is upbeat regarding the acquisition of the PIAA acquisition and notes it will expand its offering of products and services for cell biology research and for the discovery and manufacture of biopharmaceuticals including recombinant proteins, antibodies and vaccines.

“The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally,” said Kieran Murphy, President and CEO of GE Healthcare Life Sciences. “GE Healthcare Life Sciences is well known for its expertise in the “downstream” processes of biopharmaceutical manufacturing. Adding “upstream” capabilities will enable us to provide an end-to-end, fully integrated service to our customers. We believe that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product and reduce time to market.”

Lastly, GE Healthcare noted that assuming regulatory concerns pass without a hitch that the acquisition is to close during Q3, 2011.



Latest News

Terex  Earns “Hold” Rating from Barclays
Terex Earns “Hold” Rating from Barclays
Timken  Lowered to “Neutral” at Bank of America
Timken Lowered to “Neutral” at Bank of America
Bank of America Begins Coverage on Thomson Reuters
Bank of America Begins Coverage on Thomson Reuters
Aqua America  Earns Buy Rating from Analysts at Bank of America
Aqua America Earns Buy Rating from Analysts at Bank of America
Barclays Reiterates Buy Rating for Vulcan Materials
Barclays Reiterates Buy Rating for Vulcan Materials
Argus Increases Williams-Sonoma  Price Target to $73.00
Argus Increases Williams-Sonoma Price Target to $73.00


© 2006-2019 Ticker Report